An Alaska psychedelic task force is recommending that the state move forward with plans to provide regulated access to psychedelics if the federal Food and Drug Administration (FDA) allows medical use of substances such as psilocybin and MDMA.

According to a law approved in 2024, after working for about a year studying the issue, Alaska Legislative Task Force on Psychedelic Drug Regulation released its findings and recommendations on Thursday.

“Alaska has one of the nation’s highest rates of domestic violence survivors and combat veterans suffering from PTSD, and many Alaskans continue to struggle with traditional treatments,” Sen. Forrest Dunbar (D), the task force’s leader, said in a press release.

“Our approach to these new medical therapies must be properly and independently evaluated so that if the legislature were to make policy changes, we will do so with empirical data in a properly controlled environment,” the senator said.

The panel’s report lists a number of findings based on a review of the scientific literature and expert testimony. This includes findings that some psychedelics do indeed have “potential therapeutic uses” and that “there is a particular focus on the use of these therapies for veterans, survivors of assault and interpersonal violence, and others with post-traumatic stress disorder (PTSD).

Members emphasized the importance of delivering psychedelic therapies in partnership with “multiple types of providers” to provide comprehensive treatment, rather than leaving it up to the patient.

Among its recommendations, the task force said, “If psychedelic medical therapies are approved by the FDA, the state should take steps to allow them to be used in Alaska, rather than ban their use.”

Alaska regulators should also identify clinical task forces, “whose role is to regularly review up-to-date studies and the evidence base to make recommendations, and rely on those entities to provide ongoing guidance on the use of these therapies,” he said.

“As much as possible, reserve the use of state statute for broad enabling language and essential components of a regulatory structure, and leave most regulatory decisions to the appropriate boards and agencies,” another recommendation reads. “Regulations still require a robust public process to be approved, but they are more predictable and can be updated or changed more easily than statutory amendments that require legislative action.”

“The appropriate parameters for the use of these therapies are likely to change over time as the evidence base matures and FDA approval may be granted for multiple therapies,” he said.

If the FDA continues to approve any psychedelics for medical use, the panel said the Alaska State Board of Medicine should update its guidelines for prescribing controlled substances to include new therapies.

Additionally, if the FDA approves psychedelic drugs and the Drug Enforcement Administration (DEA) federally reschedules substances such as psilocybin, Alaska “should fully reflect federal programming and Risk Evaluation and Mitigation Strategies (REMS), without adding duplicative or conflicting state regulations, and follow the rules for determining whether a DEA license is required.” the report he says

“This approach respects federal science and facilitates access for patients and providers,” he continues.

Additionally, as lawmakers and regulators await a federal decision to advance psychedelic therapies, states should consider legislation to “incorporate the recommendations made in this report to encourage statewide implementation action.”

“Legislation on triggers would require addressing various process and regulatory issues, such as the role and involvement of professional licensing boards, state agencies, and the Controlled Substances Advisory Committee,” the task force said.

The report also says that psychedelic reform should include military veterans’ access to FDA-approved therapies, which could involve working with the US Department of Veterans Affairs (VA) to identify opportunities to participate in clinical trials and pilot programs using new drugs.

“The grant should be considered to ensure active efforts by the American Medical Association (AMA) and the Centers for Medicare and Medicaid Services (CMS) to develop billing codes that will promote sufficient reimbursement for the provision of psychedelic therapy, which are essential to ensure patient access post-FDA approval,” the panel said.

Rep. Justin Ruffridge (R), who also serves as co-chair of the psychedelic panel, said the task force “focused on preparing Alaska for potential federal approval of psychedelic therapies.”

“These recommendations came from months of collaboration and work by medical professionals, advocates and legislators who focused on patient safety, evidence-based care and access, especially for those who have not seen progress through traditional treatments,” he said.

So far two other states have facilitated fully functioning psychedelic programs. Oregon voters legalized the therapeutic psilocybin in 2020and Colorado’s program was approved at the ballot box in 2022, with the state’s governor signing the legislation a year later to create the regulatory framework for the program

Meanwhile, a campaign in Alaska announced in December that it did not get enough signaturesAn initiative to legalize some psychedelics like psilocybin and DMT on the 2026 state ballot.– but the activists have emphasized that “the work is far from over” as they focus on putting the reform measure before the voters in 2028.

“While we won’t be on the ballot in 2026, we’re still on track for 2028, and with the determination, focus and support of our community, we’ll continue to move forward,” Natural Medicine Alaska said in December. “This movement is gaining momentum every day. In fact, 65 percent of Alaskans support this initiative, and that number continues to grow.”

A pre-campaign policy outline explained that the proposal is “under construction”. The Natural Medicine Health Act of 2022 passed by Colorado votersunder last year facilitators administered the state’s first legal dose of psilocybin.

A 2024 poll found that nearly half (49.4 percent) of Alaskan adults would support a ballot measure more broadly. remove criminal penalties for the use of substances such as psilocybin mushrooms.

That support rose significantly—to nearly two-thirds (65 percent)—when participants were told that Alaska has high rates of mental illness that could be treated with psychedelics.

Photo elements courtesy of the user carlosemmaskype and Apollo.